Pluristem Therapeutics (NASDAQ:PSTI) +8.4% premarket after it responds to a Bloomberg article that says the second of three patients given PSTI’s experimental stem cells died after the company touted the treatments as “life-saving." PSTI wants Bloomberg to publish a correction because the article is "factually inaccurate and misleading."